PsyMed Ventures is a San Francisco-based venture capital firm founded in 2020 by Dina Burkitbayeva, Greg Kubin, and Matias Serebrinsky, with a mission to invest in frontier technologies revolutionizing brain and mental health, particularly psychedelic medicine, neurotechnology, precision psychiatry, digital therapeutics, and AI-driven approaches. The firm manages a $25 million fund announced in 2022, alongside an active angel syndicate, focusing on early-stage startups that address root causes of mental health issues amid a global crisis affecting billions. With over 30 investments as of 2025, notable portfolio companies include Delix Therapeutics and Freedom Biosciences (psychedelic-derived therapeutics), ImYoo (single-cell immunology for mental health), Motif Neurotech (implantable devices for depression), and others like Journey Clinical and Remepy, supported by the founders' podcast "Business Trip" which builds community in the space.